High Dose Methylprednisolone Verses Low Dose in Correction of Congenital Acynotic Heart Disease
Primary Purpose
Anesthesia
Status
Unknown status
Phase
Phase 4
Locations
Egypt
Study Type
Interventional
Intervention
methyl prednisolone
Methyl Prednisolonate
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Anesthesia
Eligibility Criteria
Inclusion Criteria:
- We will include pediatric patients ( 1- 16) years old undergoing surgical correction for congenital acyanotic cardiac lesions needing cardiopulmonary bypass machine.
Exclusion Criteria:
- 1) Cyanotic heart disease. 2) Closed cardiac surgeries. 3) Previous cardiac surgery. 4) Patients suffering neurological illness. 5) Diabetics. 6) Emergency procedures. 7) Patients on preoperative steroid therapy. 8) Adult patients with congenital heart disease.
Sites / Locations
- Samar mohammedRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Placebo Comparator
Arm Label
low dose group
high dose group
Placebo group
Arm Description
low dose group. Group (A) (25 patients) patients will receive 10 mg/Kg methyl prednisolone after induction before separation to (CPB).
high dose group. Group (B) (25 patients) patients will receive 30 mg/Kg methyl prednisolone after induction before separation to (CPB).
placebo group. Group (C) (control group)(25 patients) patients will receive placebo in form of normal saline.
Outcomes
Primary Outcome Measures
assessment of Level of IL 6 after CPB time
comparing level of IL6 in different groups after CPB
Secondary Outcome Measures
Less postoperative complications related to high doses of steroid represented as blood glucose level.
comparing Less postoperativecomplications related to high doses of steroid represented as blood glucose level.
Full Information
NCT ID
NCT05103397
First Posted
October 22, 2021
Last Updated
November 1, 2021
Sponsor
Ain Shams University
1. Study Identification
Unique Protocol Identification Number
NCT05103397
Brief Title
High Dose Methylprednisolone Verses Low Dose in Correction of Congenital Acynotic Heart Disease
Official Title
High Dose Methylprednisolone Verses Low Dose in Correction of Congenital Acynotic Heart Disease
Study Type
Interventional
2. Study Status
Record Verification Date
October 2021
Overall Recruitment Status
Unknown status
Study Start Date
October 16, 2021 (Actual)
Primary Completion Date
January 15, 2022 (Anticipated)
Study Completion Date
January 30, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ain Shams University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
To compare the effect of low dose methylprednisolone versus high dose on inflammatory mediators' level and cardioprotective effect after CPB in correction of congenital acyanotic heart disease.
Detailed Description
This study is a prospective, randomized controlled trial, at Ain Shams University hospitals, Cardiovascular surgery hospital (cardiac surgery unit), Cairo, Egypt.
All patients' legal guardians will sign written informed consent before inclusion.
Randomization will be performed using a computer-generated randomization sequence.
Complete blood count, coagulation tests will be performed for all patients prior to the planned procedure. For all patients included in this study preoperative evaluation including a complete airway evaluation (mouth opening, mallampatii grading, thyromental distance, and evaluation of dentition) will be performed. Standard fasting guidelines will be checked. (Barash PG et al., 2006).
On patient's arrival to operating room, either inhalational induction by sevoflurane 4-6 % followed by an intravenous (IV) line insertion or IV induction by Ketamine 1-2 mg /kg and 0.01 mg / kg Atropine. Standard monitoring including electrocardiography (ECG), pulse oximetry (SpO2). Anesthesia technique: fentanyl 1-5 microgram/kg, will be given during mask preoxygenation with 100% oxygen, followed by non-depolarizing muscle relaxant (atracurium 0.5 mg /Kg) and then endotracheal intubation and capnography will be applied (Barash PG et al., 2006).
Femoral artery cannulation by 20 G Leader catheter cannula for invasive blood pressure (BP)measurement, triple lumen central line will be inserted in internal jugular vein (BRAUN) by ultrasound guided technique.
After achievement of anesthesia and full muscle relaxation and intubation of the airway, a blood sample ( 2 ml) will be taken to measure (IL6), Troponin I and blood glucose level. Skin incision will take place followed by median sternotomy. Heparin 300-500 IU/kg will be given before aortic cannulation to achieve ACT of 450-480 before starting CPB. Patients will then be divided into 3 groups:
Group (A) (25 patients) patients will receive 10 mg/Kg methyl prednisolone after induction before separation to (CPB). (Schroeder et al.,2003).
Group (B) (25 patients) patients will receive 30 mg/Kg methyl prednisolone after induction before separation to (CPB). (Keski-Nisula et al., 2013).
Group (C) (control group)(25 patients) patients will receive placebo in form of normal saline.
We will study the different doses of methylprednisolone as there is no standard dose confirmed in pediatric cardiac surgery. We will compare the low dose with high dose of this drug to decrease the different side effects of steroids, and we will detect the efficacy by measuring the inflammatory markers. In our institute the IL 6 is the only available marker to be measured.
The attending doctor will not give the drug, as another doctor not attending the surgery will give it. Both the attending doctor and intensivist will be blinded to the drug given.
After surgical correction of cardiac lesion and separation of cardiopulmonary bypass machine, support of the heart will be achieved and maintained by millirone 0.3-0.7 ug/Kg/min together with noradrenaline0.01-1 ug/Kg/min. Reversal of heparin by protamine sulphate 1:1 correction. Vital data, blood pressure and heart rate will be recorded every 10 minutes, the need or the dose of vasopressors needed will be recorded. After hemostasis and chest closure, patients will be transferred to ICU (Barash PG et al., 2006).
After admission to ICU, stabilization of patient, another blood sample of (2 ml) to measure (IL6) , troponin and random blood sugar will be taken, and a third sample will be withdrawn after 24 hours. Vital data will be recorded every 30 minutes till extubation. Time of extubation will be recorded. Complications like neurological events, occurrence of new arrhythmia, wound infection, ICU stay and mortality in the first seven days postoperative will also be recorded.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anesthesia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
75 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
low dose group
Arm Type
Active Comparator
Arm Description
low dose group. Group (A) (25 patients) patients will receive 10 mg/Kg methyl prednisolone after induction before separation to (CPB).
Arm Title
high dose group
Arm Type
Active Comparator
Arm Description
high dose group. Group (B) (25 patients) patients will receive 30 mg/Kg methyl prednisolone after induction before separation to (CPB).
Arm Title
Placebo group
Arm Type
Placebo Comparator
Arm Description
placebo group. Group (C) (control group)(25 patients) patients will receive placebo in form of normal saline.
Intervention Type
Drug
Intervention Name(s)
methyl prednisolone
Other Intervention Name(s)
steroid
Intervention Description
Low dose group .Group (A) 10 mg/Kg methyl prednisolone will be received after induction and before separation to (CPB).
Intervention Type
Drug
Intervention Name(s)
Methyl Prednisolonate
Other Intervention Name(s)
steroid
Intervention Description
High dose group.Group (B) 30 mg/Kg will be received after induction and before separation (CPB)
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo group.Group (C) (25 patients) patients will receive placebo in form of normal saline
Primary Outcome Measure Information:
Title
assessment of Level of IL 6 after CPB time
Description
comparing level of IL6 in different groups after CPB
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Less postoperative complications related to high doses of steroid represented as blood glucose level.
Description
comparing Less postoperativecomplications related to high doses of steroid represented as blood glucose level.
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
We will include pediatric patients ( 1- 16) years old undergoing surgical correction for congenital acyanotic cardiac lesions needing cardiopulmonary bypass machine.
Exclusion Criteria:
1) Cyanotic heart disease. 2) Closed cardiac surgeries. 3) Previous cardiac surgery. 4) Patients suffering neurological illness. 5) Diabetics. 6) Emergency procedures. 7) Patients on preoperative steroid therapy. 8) Adult patients with congenital heart disease.
Facility Information:
Facility Name
Samar mohammed
City
Cairo
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
maha Sadek elDerh, Lecturer
Phone
0224190092
Email
mahasadek81@yahoo.com
First Name & Middle Initial & Last Name & Degree
Samar Mohammed, Lecturer
Phone
01006236494
Ext
elDerh
Email
mahasadek81@yahoo.com
First Name & Middle Initial & Last Name & Degree
maha S elDerh, lecturer
12. IPD Sharing Statement
Learn more about this trial
High Dose Methylprednisolone Verses Low Dose in Correction of Congenital Acynotic Heart Disease
We'll reach out to this number within 24 hrs